Danielle Brill
Stock Analyst at Truist Securities
(1.85)
# 3,044
Out of 4,944 analysts
82
Total ratings
33.33%
Success rate
-8.12%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Initiates: Buy | $86 | $61.10 | +40.75% | 6 | Jul 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Buy | $385 | $432.52 | -10.99% | 1 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $36.67 | +30.90% | 8 | Jul 21, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $56 | $44.64 | +25.45% | 1 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $22.08 | +189.92% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $131.62 | +23.84% | 6 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $66 | $50.38 | +31.00% | 1 | Jul 21, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $30 | $17.14 | +75.03% | 1 | Jul 21, 2025 | |
| JCAP Jefferson Capital | Initiates: Buy | $24 | $18.36 | +30.72% | 1 | Jul 21, 2025 | |
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $14.60 | +256.16% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.81 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $58.30 | +35.51% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $8.93 | +101.57% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $36 | $15.89 | +126.56% | 4 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $20.40 | +635.29% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $135.19 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $395.92 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $646.60 | -6.43% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $25.13 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $37.67 | +32.73% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $36.61 | +39.31% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $6.38 | +1,467.40% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $48.17 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.88 | - | 5 | Jun 27, 2023 |
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $61.10
Upside: +40.75%
Alnylam Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $385
Current: $432.52
Upside: -10.99%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $36.67
Upside: +30.90%
Palvella Therapeutics
Jul 21, 2025
Initiates: Buy
Price Target: $56
Current: $44.64
Upside: +25.45%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $22.08
Upside: +189.92%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $131.62
Upside: +23.84%
BridgeBio Pharma
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $50.38
Upside: +31.00%
Centessa Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $17.14
Upside: +75.03%
Jefferson Capital
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.36
Upside: +30.72%
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.60
Upside: +256.16%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.81
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $58.30
Upside: +35.51%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.93
Upside: +101.57%
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $15.89
Upside: +126.56%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $20.40
Upside: +635.29%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $135.19
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $395.92
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $646.60
Upside: -6.43%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $25.13
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $37.67
Upside: +32.73%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $36.61
Upside: +39.31%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $6.38
Upside: +1,467.40%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $48.17
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.88
Upside: -